HBV immunotherapeutic
- Health
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.: Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and…
Read More »